Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

editorial

. 2021 Apr 20;1(1):5–7. doi: 10.1097/ID9.0000000000000005

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 The Chinese Medical Association, published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Hypothetical pathogenesis of COVID-19. The X-axis is the number of days after SARS-CoV-2 infection, and it is divided into three phases according to the above conjecture. The Y-axis is the trend of T cells, B cells, inflammatory factors, d-dimer and viral load in patients. (A) The trend of each indicator in COVID-19 patients with severe type. (B) The trend of each indicator in COVID-19 patients with severe type after LWMH and IVIG therapy. The shaded areas represent the recommended intervention times for LMWH and IVIG treatment.^[1] IVIG: intravenous immunoglobulin; LWMH: low molecular weight heparin.